JAK2 (V617F)-pcw107-V5 Citations (4)

Originally described in: Systematic identification of signaling pathways with potential to confer anticancer drug resistance.
Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff M, Chen PL, Rathmell JC, Flaherty KT, Wargo JA, McDonnell DP, Sabatini DM, Wood KC Sci Signal. 2014 Dec 23;7(357):ra121. doi: 10.1126/scisignal.aaa1877. PubMed Journal

---

Articles Citing JAK2 (V617F)-pcw107-V5

Articles
Molecular mechanisms for enhancement of stromal cell-derived factor 1-induced chemotaxis by platelet endothelial cell adhesion molecule 1 (PECAM-1). Umezawa Y, Akiyama H, Okada K, Ishida S, Nogami A, Oshikawa G, Kurosu T, Miura O. J Biol Chem. 2017 Dec 1;292(48):19639-19655. doi: 10.1074/jbc.M117.779603. Epub 2017 Oct 3. PubMed
Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation. Arenas EJ, Martinez-Sabadell A, Rius Ruiz I, Roman Alonso M, Escorihuela M, Luque A, Fajardo CA, Gros A, Klein C, Arribas J. Nat Commun. 2021 Feb 23;12(1):1237. doi: 10.1038/s41467-021-21445-4. PubMed
Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer. Wang W, Tang YA, Xiao Q, Lee WC, Cheng B, Niu Z, Oguz G, Feng M, Lee PL, Li B, Yang ZH, Chen YF, Lan P, Wu XJ, Yu Q. Nat Commun. 2021 Jul 21;12(1):4441. doi: 10.1038/s41467-021-24687-4. PubMed
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. Yang J, Weisberg EL, Liu X, Magin RS, Chan WC, Hu B, Schauer NJ, Zhang S, Lamberto I, Doherty L, Meng C, Sattler M, Cabal-Hierro L, Winer E, Stone R, Marto JA, Griffin JD, Buhrlage SJ. Leukemia. 2022 Jan;36(1):210-220. doi: 10.1038/s41375-021-01336-9. Epub 2021 Jul 29. PubMed

If you have published an article using this material, please email us at to have your article added to this page.